crofelemercrow-fel-e-mur(Fulyzaq)uCLASSIFICATIONPHARMACOTHERAPEUTIC:

Chloride ion inhibitor. CLINICAL: Antidiarrheal agent.ACTIONInhibits calcium-activated

chloride chan-nel at the luminal membrane of entero-cytes, blocking secretion and high-vol-ume
water loss in diarrhea, normalizing the flow of chloride and water in the gastrointestinal tract.
Therapeutic Ef-fect: Antidiarrheal.PHARMACOKINETICSMinimal absorption. Half-life:
N/A.USESSymptomatic relief of noninfectious diar-rhea in adult pts with HIV, AIDS who are
receiving antiretroviral therapy.PRECAUTIONSContraindications: None known. Cau-tions: Do
not use in those with infectious diarrhea. Electrolyte imbalance, fluid depletion. LIFESPAN
CONSIDERATIONSPregnancy/Lactation: Unknown if dis-tributed in breast milk. Pregnancy
Cate-gory C.Children: Safety and efficacy not established in those younger than 18 yrs of age.
Elderly: No age-related precau-tions noted.INTERACTIONSDRUG: None significant.
HERBAL: None significant. FOOD: None known. LABVAL-UES: May increase serum
bilirubin, AST. May decrease WBC count.AVAILABILITY (Rx)Tablets,Delayed-Release: 125
mg.ADMINISTRATION/HANDLINGPO• Give without regard to food. • Swallow whole. • Do
not break, crush, dissolve, or divide
tablet.INDICATIONS/ROUTES/DOSAGEDiarrheaPO:ADULTS,ELDERLY: One tablet two
times daily.SIDE EFFECTSOccasional(4%–3%): Cough, flatulence, nausea, back pain,
arthralgia. Rare(2%–1%): Nasopharyngitis, musculoskeletal pain, anxiety, abdominal distention,
dry mouth, constipation.ADVERSEEFFECTS/TOXICREACTIONSUpper respiratory tract
infection occurs in 6% of pts, bronchitis in 4%, urinary tract infection in
2%.NURSINGCONSIDERATIONS